Good posts maui & tanis! you both have good points! My

New Post Public Reply Private Reply Replies (1) Message Board
jamiejaytrader
Good posts maui & tanis! you both have good points!

My own thoughts:

I'm confident amarantus will be succesfull eventually and especially with ESS.

Now my concern is the toxics and the increasing outstanding shares (currently around 30million i believe).

with what has been said by Gerald that we should be valued like our peers with around a 250-300million market cap, lets assume 300million for now.

so we should be valued around $10 (but we are not because of the toxics!).
(30million outstanding shares x $10 = 300 million market cap).

Now if the toxics keep diluting us and the outstanding shares keep on growing and i'm going to take the absurd route here to make my point clearer, so for example lets say we dilute another 70 million shares, so a total of 100millions outstandings shares we have now.

That means 100million outstanding shares x $3 = 300 million market cap.

So are share price if valued properly will be only $3.

Its gets worse of course if we get more diluted etc...

For those that bought around the $28 dollars (like me) and did not have the funds to average down (i did average down hard at 45 cents but my average is still close to $3 still i believe), the investors will likely won't see their original investment of $28 dollars back because of the dilution by the toxics thats going on.

I might make my post to complicated for some to understand but the simple point i'm making and what tanis is also saying from what i understood is that the more shares that get diluted the less return we will see with our investment.

So taking out the toxics asap is KEY!

I know amarantus is trying to do so and hopefully they will succeed.

My other thought is this:
From the interview yesterday i believe gerald will most likely spin out ESS to another company.
IF that happens i hope we get some much needed cash instead of shares for ESS so we can remove the toxics AND have working capital so that we can move the therapeutic pipeline forward and that our share price can start recovering from the damage done by the toxic investors.

It will be very interesting to see how plans will unfold with ESS.
We have the potential of greatness but our fates lies in the hands of management.

I personally would sell or partner an asset (or multiple) to take out the toxics and to create shareholder value.

Also on option would be if management would spin out ESS and give shareholders a share dividend in the new company with lots of value and liquidity.
A reward for loyal shareholders.

We'll see how things will turn out the next few weeks/months.

I would love to hear others opinions on this matter, lets hear some more thoughts and debate

Have a nice weekend everyone!


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 5

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 4

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 7

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 6

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Portable Battery Charger Set to Transform EV Charging

Updated Category News Views 207

Introduction to the New Battery Charger for Electric Vehicles In a world where electric vehicles (EVs) are becoming more prevalent, the quest for convenience and reliability in charging options has led to the creation of an exciting new product. An inventive mind has developed a portable battery charger designed specifically for electric cars, addressing the significant...

Continue Reading
How to Calculate Rental Property Returns in Calgary

Updated Category Real Estate Views 549

The growth of the future value is not sufficient to invest in rental property, particularly in a market place such as Calgary where the economic cycles and population dynamics may affect the results. By computing the returns on the rental property, investors are able to know whether a property will be able to produce sustainable returns as they accumulate long te

Continue Reading
Understanding BioCardia's Upcoming Earnings Announcement

Updated Category News Views 196

BioCardia's Anticipated Earnings Report BioCardia (NASDAQ: BCDA) is gearing up for its next quarterly earnings announcement. Investors are keen to hear the results as they look to gain insights into the company's performance and future expectations. Expected Earnings Per Share Current estimates suggest that BioCardia will report an earnings per share (EPS) of...

Continue Reading
A New Look at Trump's First Month and Children's Concerns

Updated Category News Views 501

President Trump's Impact During His Initial Month As President Trump's new term unfolds, impactful events are shaping his administration's direction. The first month has been marked by significant developments, highlighted by the Senate's confirmation of Kash Patel as the Director of the FBI. This move is seen as a pivotal moment, emphasizing a commitment to addressing...

Continue Reading
Eramet Faces Revenue Decrease Amid Logistics Hurdles

Updated Category News Views 286

Eramet Revenue Decline in Q3 2025 Eramet has reported a decline in its adjusted turnover for the third quarter of 2025, which totaled €720 million. This marks a 10% decrease compared to the same quarter in 2024. The decrease primarily stems from significant external factors affecting sales and market conditions. Safety and CSR Achievements Despite facing a challenging...

Continue Reading